Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA

被引：9

作者：

Johnson, Alison C. ^{[1
]}

Do, Pascal ^{[1
]}

Richard, Nicolas ^{[2
]}

Dubos, Catherine ^{[1
]}

Michels, Jean Jacques ^{[3
]}

Bonneau, Jessica ^{[4
]}

Gervais, Radj ^{[1
]}

机构：

[1] Ctr Francois Baclesse, Dept Oncol, F-14000 Caen, France

[2] CHU Caen, Dept Genet, F-14000 Caen, France

[3] Ctr Francois Baclesse, Dept Pathol, F-14000 Caen, France

[4] CHU Caen, GENECAN Platform, F-14000 Caen, France

来源：

LUNG CANCER | 2016年 / 99卷

关键词：

Non-small cell lung cancer; ALK; Crizotinib; Resistance mutation; Circulating tumor DNA; NSCLC PATIENTS; CRIZOTINIB;

D O I：

10.1016/j.lungcan.2016.06.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is sensitive to ALK inhibitor therapy, but resistance invariably develops and can be mediated by certain secondary mutations. The detection of these mutations is useful to guide treatment decisions, but tumors are not always easily accessible to re-biopsy. We report the case of a patient with ALK-rearranged NSCLC who presented acquired resistance to crizotinib and then alectinib. Sequencing analyses of DNA from a liver metastasis biopsy sample and circulating tumor DNA both found the same I1171N ALK kinase domain mutation, known to confer resistance to certain ALK inhibitors. However, the patient then received ceritinib, a 2nd generation ALK inhibitor, and achieved another partial response. This case underlines how ALK resistance mutation detection in peripheral blood could be a reliable, safer, and less invasive alternative to tissue-based samples in NSCLC. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：38 / 40

页数：3

共 13 条

[1] Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing [J].

Chan, K. C. Allen ;

Jiang, Peiyong ;

Zheng, Yama W. L. ;

Liao, Gary J. W. ;

Sun, Hao ;

Wong, John ;

Siu, Shing Shun N. ;

Chan, Wing C. ;

Chan, Stephen L. ;

Chan, Anthony T. C. ;

Lai, Paul B. S. ;

Chiu, Rossa W. K. ;

Lo, Y. M. D. .

CLINICAL CHEMISTRY, 2013, 59 (01) :211-224

[2] Detection of tumor ALK status in neuroblastoma patients using peripheral blood [J].

Combaret, Valerie ;

Iacono, Isabelle ;

Bellini, Angela ;

Brejon, Stephanie ;

Bernard, Virginie ;

Marabelle, Aurelien ;

Coze, Carole ;

Pierron, Gaelle ;

Lapouble, Eve ;

Schleiermacher, Gudrun ;

Blay, Jean Yves .

CANCER MEDICINE, 2015, 4 (04) :540-550

[3] Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer [J].

Imamura, Fumio ;

Uchida, Junji ;

Kukita, Yoji ;

Kumagai, Toru ;

Nishino, Kazumi ;

Inoue, Takako ;

Kimura, Madoka ;

Oba, Shigeyuki ;

Kato, Kikuya .

LUNG CANCER, 2016, 94 :68-73

[4] Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma [J].

Janoueix-Lerosey, Isabelle ;

Lequin, Delphine ;

Brugieres, Laurence ;

Ribeiro, Agnes ;

de Pontual, Loic ;

Combaret, Valerie ;

Raynal, Virginie ;

Puisieux, Alain ;

Schleiermacher, Gudrun ;

Pierron, Gaelle ;

Valteau-Couanet, Dominique ;

Frebourg, Thierry ;

Michon, Jean ;

Lyonnet, Stanislas ;

Amiel, Jeanne ;

Delattre, Olivier .

NATURE, 2008, 455 (7215) :967-U51

[5] Identification of ALK as a major familial neuroblastoma predisposition gene [J].

Mosse, Yael P. ;

Laudenslager, Marci ;

Longo, Luca ;

Cole, Kristina A. ;

Wood, Andrew ;

Attiyeh, Edward F. ;

Laquaglia, Michael J. ;

Sennett, Rachel ;

Lynch, Jill E. ;

Perri, Patrizia ;

Laureys, Genevieve ;

Speleman, Frank ;

Kim, Cecilia ;

Hou, Cuiping ;

Hakonarson, Hakon ;

Torkamani, Ali ;

Schork, Nicholas J. ;

Brodeur, Garrett M. ;

Tonini, Gian P. ;

Rappaport, Eric ;

Devoto, Marcella ;

Maris, John M. .

NATURE, 2008, 455 (7215) :930-U22

[6] I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib [J].

Ou, Sai-Hong Ignatius ;

Greenbowe, Joel ;

Khan, Ziad U. ;

Azada, Michele C. ;

Ross, Jeffrey S. ;

Stevens, Phil J. ;

Ali, Siraj M. ;

Miller, Vincent A. ;

Gitlitz, Barbara .

LUNG CANCER, 2015, 88 (02) :231-234

[7] Identification of a Novel HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib [J].

Ou, Sai-Hong Ignatius ;

Klempner, Samuel J. ;

Greenbowe, Joel R. ;

Azada, Michele ;

Schrock, Alexa B. ;

Ali, Siraj M. ;

Ross, Jeffrey S. ;

Stephens, Philip J. ;

Miller, Vincent A. .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (12) :1821-1825

[8] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer [J].

Shaw, Alice T. ;

Kim, Dong-Wan ;

Nakagawa, Kazuhiko ;

Seto, Takashi ;

Crino, Lucio ;

Ahn, Myung-Ju ;

De Pas, Tommaso ;

Besse, Benjamin ;

Solomon, Benjamin J. ;

Blackhall, Fiona ;

Wu, Yi-Long ;

Thomas, Michael ;

O'Byrne, Kenneth J. ;

Moro-Sibilot, Denis ;

Camidge, D. Ross ;

Mok, Tony ;

Hirsh, Vera ;

Riely, Gregory J. ;

Iyer, Shrividya ;

Tassell, Vanessa ;

Polli, Anna ;

Wilner, Keith D. ;

Jaenne, Pasi A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25) :2385-2394

[9]

Shen L, 2014, NEW ENGL J MED, V370, P2537, DOI [10.1056/NEJMoa1311107, 10.1056/NEJMc1404894]

[10] ALK-Positive Non-Small Cell Lung Cancer Mechanisms of Resistance and Emerging Treatment Options [J].

Steuer, Conor E. ;

Ramalingam, Suresh S. .

CANCER, 2014, 120 (16) :2392-2402

← 1 2 →